A Multi-center, Randomized, Open-label, Pilot and Exploratory Study Investigating Safety and Efficacy in OPTIMIZEd Dosing of Advagraf Kidney Transplantation in Asia.
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms OPTIMIZE
- Sponsors Astellas Pharma
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress
- 11 Jan 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.